№ files_lp_3_process_9_73027
File format: docx Character count: 83609 File size: 156 KB
Tofacitinib is presented for consideration as a treatment option for ankylosing spondylitis, comparing its efficacy and safety to adalimumab and upadacitinib.
Year: 2023
Region / city: Australia
Subject: Ankylosing spondylitis treatment
Document type: Pharmaceutical submission
Institution: Pfizer Australia Pty Ltd
Author: Pfizer Australia Pty Ltd
Target audience: Medical professionals
Period of validity: Ongoing
Approval date: 25 January 2023
Date of changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report
Year: 2020
Region / City: Shanghai, China
Subject: Medical Case Report
Document Type: Case Report
Organization / Institution: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Author: Ben Li, Guan-Wu Li, Luan Xue, Yue-Ying Chen
Target Audience: Medical Professionals, Rheumatologists
Period of Action: 2020
Date of Approval: August 29, 2020
Date of Revision: June 18, 2020
Date of Publication: October 06, 2020
Keywords: Synovitis, acne, pustulosis, hyperostosis, osteitis syndrome, JAK inhibitor, tofacitinib, case report, rheumatoid arthritis, psoriatic arthritis
DOI: https://dx.doi.org/10.12998/wjcc.v8.i19.4527
URL: https://www.wjgnet.com/2307-8960/full/v8/i19/4527.htm
Context: A medical case report describing the rapid response of a patient with SAPHO syndrome to the Janus kinase inhibitor tofacitinib after failure of conventional treatments.
METHOTREXATE, Tablet 2.5 mg (as sodium) Tablet 10 mg (as sodium), Methoblastin®, PFIZER AUSTRALIA PTY LTD
Year: 2023
Region / city: Australia
Theme: Pharmaceutical submission
Document type: Pharmaceutical submission
Organization / institution: Pfizer Australia Pty Ltd
Author: Not specified
Target audience: Medical practitioners, nurse practitioners
Effective period: Not specified
Approval date: Not specified
Amendment date: Not specified
Context: Pharmaceutical submission requesting the inclusion of a new formulation of methotrexate under the General Schedule of the PBS for Australia, with changes in packaging and excipient composition.
PNEUMOCOCCAL CONJUGATE VACCINE, 20-VALENT, 0.5 mL pre-filled syringe, Prevenar 20®, PFIZER AUSTRALIA PTY LTD
Year: 2023
Region / city: Australia
Subject: Pneumococcal vaccine
Document type: Submission
Organ / institution: Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Pfizer Australia Pty Ltd
Target audience: Healthcare professionals, public health policymakers
Period of validity: Ongoing
Approval date: 27 April 2023 (FDA approval)
Amendment date: 20 December 2022 (TGA submission)
Background: This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Gemtuzumab Ozogamicin, Powder for Injection 5 mg, Mylotarg®, Pfizer Australia Pty Ltd.
Year: 2020
Region / city: Australia
Therapeutic area: Oncology
Document type: Regulatory submission
Institution: Pfizer Australia Pty Ltd.
Author: Pfizer Australia Pty Ltd.
Target audience: Regulatory authorities, medical professionals
Effective period: Ongoing
Approval date: April 9, 2020
Date of last revision: March 2021
Topics: Xeljanz TOFACITINIB PFIZER